drugset / Trial / NCT01261572

Study to Find Maintenance Dose for Periodic Administration of ASP3550

NCT01261572

Phase 2 Completed 155 enrolled Astellas Pharma Inc
RandomizedParallel-groupOpen-labelTreatment

Summary

To find effective doses of ASP3550 on the maintenance of serum testosterone suppression in patients with prostate cancer.

Timeline

Start
2010-10-12
Primary completion
2012-04-24
Completion
2012-04-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Degarelix Other / unclassified

Indications